China has slashed the price of dozens of top drugs from multinationals such as Roche, GlaxoSmithKline and AstraZeneca by as much as 70 per cent as a condition of adding them to a government health insurance scheme.
manbetx3.0 促使罗氏(Roche)、葛兰素史克(GSK)和阿斯利康(AstraZeneca)等跨国公司将数十种重点药品降价，其中降幅最高的达到70%，以此为条件将这些药品纳入政府医保药品目录。
您已阅读11%（306字），剩余89%（2536字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。